AxoGen Stock Rockets 12% on Q1 2026 Revenue Beat, Raised Guidance and Debt-Free Balance Sheet

Fuente: International Business Times

AxoGen Stock Rockets 12% on Q1 2026 Revenue Beat, Raised Guidance and Debt-Free Balance Sheet NEW YORK — AxoGen Inc. shares surged more than 11% on Tuesday, April 28, 2026, climbing to $43. 98 in morning trading after the peripheral nerve repair company delivered a strong first-quarter revenue beat, posted adjusted profitability and raised its full-year 2026 guidance while announcing it had become debt-free following a successful public offering.